Hematology TimesCombo proves ‘beneficial’ for ‘unfit’ CLL patientsJune 20, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesPeripheral blood MRD correlates with treatment benefit in CLLJune 18, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesIbrutinib and venetoclax combo promising in frontline CLLJune 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesChemo-free combo provides potential first-line option for FLJune 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA approves venetoclax for CLL/SLL with or without del 17pJune 10, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesPolatuzumab plus BR improves efficacy in DLBCLJune 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesSingle-agent acalabrutinib ‘impressive’ in patients with WMJune 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesOlder, cheaper drug formulation to remain availableMay 21, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesRegimen can improve DFS in newly diagnosed T-ALLMay 17, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin Lymphoma
Hematology TimesUmbralisib has ‘distinct’ safety profileMay 16, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesTeam identifies new prognostic factor for MFMay 10, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesDrug granted fast track designations for FL, DLBCLMay 5, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA issues CRL for proposed biosimilar rituximabMay 3, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA approves CAR T-cell therapy for lymphomaMay 2, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesPredicting response to CAR T-cell therapy in CLLMay 1, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
